AU5564299A - Antimicrobial peptides isolated from the skin of american frogs - Google Patents

Description

WO 00/09553 PCT/US99/18575 ANTIMICROBIAL PEPTIDES ISOLATED FROM THE SKIN OF AMERICAN FROGS This application is based on U.S. Provisional Application 5 Serial No. 60/096,607, filed August 14, 1998. Background of the Invention The indiscriminate use of antibiotics in hospitals has created drug resistant pathogens that cause difficult-to-cure infections. This problem is particularly serious in the case of AIDS, tuberculosis and other 10 immunocompromised patients. For example, data collected by the Synercid Microbiology Assessment of Resistance Trends surveillance project have shown that more than 31% of 17,000 bacterial isolates of Streptococcus pneumoniae obtained from patients at U.S. hospitals were intermediately or completely resistant to penicillin. The incidence of methicillin-resistant strains of 15 Staphylococcus aureus was shown by this project to be 29%. Tuberculosis, which was allegedly eradicated in the United States, has made a horrific reappearance in forms that are resistant to traditional isoniazid therapy. Bacterial infection in animals has also become drug-resistant in some cases. The economic toll is staggering as well. It has been estimated that drug-resistant 20 infections acquired in hospitals nearly triple the cost and duration of an average hospital stay. Hoffert, S.P., "Companies seeking solutions to emerging drug resistance," The Scientist, 12(8), 1-6 (1998). As a result of earlier dramatic successes in the development of antimicrobial agents, most large pharmaceutical companies during the 1980s and 25 early 1990s cut back or eliminated programs of research and development of new compounds on the grounds that the battle against infectious diseases had been won. However, the emergence of increasing numbers of pathogenic microorganisms with resistance to the commonly used antibiotics has greatly stimulated searches for novel antimicrobial agents to fight drug-resistant 30 infections.

WO 00/09553 PCT/US99/18575 Among those searches is the investigation of novel antibiotic peptides from Anuran (frog and toad) skin. Amphibians of necessity live in a warm, moist environment that is particularly conducive to the growth of microorganisms. As a result, Anurans have evolutionarily developed effective 5 strategies for their own protection. In particular, Anurans synthesize polypeptides with a broad spectrum of antimicrobial activity through the granular glands present in their skin. The bioactive peptides are released into skin secretions in a holocrine fashion upon stress or injury and protect against invasion by pathogenic microorganisms. The 10 amphibian antimicrobial peptides are generally synthesized as members of structurally-related families and examples include magainins from Xenopus laevis, bombinins from Bombina variegata and Bombina orientalis, dermaseptins from Phyllomedusa sauvagii and Phyllomedusa bicolor, buforins from Bufo bufo gargarizans, and caerins from Litoria chloris and Litoria 15 splendida. Despite the sequence similarities, the members of a particular family have distinct spectra of antimicrobial activity and it has been speculated that this molecular diversity is important in protecting the animal from invasion by a wide array of different microorganisms. Frogs from the genus Rana constitute an extremely diverse and widely 20 distributed group with an estimated 250 species worldwide and at least 36 species having been identified in North America (12 delete). Analysis of skin secretions and/or skin extracts of different species of Ranid frogs has led to the following characterizations: 1) gaegurins and rugosins from R. rugosa, 2) brevinins from R. brevipoda porsa, R. esculenta and R. sphenocephala, 3) 25 esculentins from R. esculenta, 4) ranalexin and ranatuerins from R. catesbeiana and 5) temporins and ranatuerin 1T from R. temporaria. Peptides of the brevinin family have also been isolated from an extract of gastric tissue from R. esculenta. Further examples of such peptides are discussed in: 2 WO 00/09553 PCT/US99/18575 1) Lazarus, L.H., and Attila, M., "The toad, ugly and venomous, wears yet a precious jewel in his skin," Prog. Neurobiol., 41, 473 507 (1993); 2) Zasloff, M., "Magainins, a class of antimicrobial peptides 5 from Xenopus skin: isolation, characterization of two active forms and partial cDNA sequence of a precursor," Proc. Natl. Acad. Sci. USA 84, 5449-5453, (1987); 3) Buforins from Bufo bufo gargarizans- Park, C.B., Kim, M.S., and Kim, S.C., Biochem. Biophys. Res. Commun., 218, 408-413, (1996); 10 4) Bombinins from Bombina variegata- Simmaco, M., Barra, D., Chiarini, F., Noviello, L., Melchiorri, P., Kreil, G., and Richter, K., "A family of bombinin-related peptides from the skin of Bombina variegata, " Eur. J. Biochem. 199, 217-222, (1991); 5) Bombina orientalis- Gibson, B.W., Tang, D., Mandrell, 15 R., Kelly, M., and Spindel, E.R., "Bombinin-like peptides with antimicrobial activity from skin secretions of the Asian toad, Bombina orientalis.," J. Bio. Chem. 266, 23103-23111, (1991); 6) Dermaseptins from Phyllomedusa sauvagii- Mor, A., Hani, K., and Nicolas, P., "The vertebrate peptide antibiotics dermaseptins have 20 overlapping structural features but target specific microorganisms," J. BioL Chem. 269, 31635-31641, (1994); 7) Caerins from Litoria chloris- Steinborner, S.T., Currie, G.J., Bowie, J.H., Wallace, J.C., and Tyler, M.J., "New antibiotic caerin 1 peptides from the skin secretion of the Australian tree frog Litoria chloris, 25 comparison of the activities of the caerin 1 peptides from the genus Litoria," J. Peptide Res. 51, 121-126, (1998); 8) Gaegurins from the Korean frog, Rana rugosa- Park, J.M., Jung, J.E., and Lee, B.J., "Antimicrobial peptides from the skin of a Korean frog, Rana rugosa," Biochem. Biophys. Res. Commun. 205, 948-954, (1994); 3 WO 00/09553 PCT/US99/18575 9) Brevinins from the Japanese frog, Rana brevipoda porsa Morikawa, N., Hagiwara, K., and Nakajima, T., "Brevinin-1 and -2, unique antimicrobial peptides from the skin of the frog, Rana brevipoda porsa," Biochem. Biophys. Res. Commun. 189, 184-190 (1992); and 5 10) Esculentins and brevinins from the European frog, Rana esculenta- Simmaco, M., Mignogna, G., Barra, D., and Bossa, F., "Antimicrobial peptides from skin secretions of Rana esculenta," J. Bio. Chem. 269, 11956-11961, (1994). Some of these peptides discussed in the art have the following sequences. 10 Gaegurin 5 FLGALFKVASKVLPSVKCAITKKC (SEQ ID NO: 1) Gaegurin 6 FLPLLAGLAANFLPTIICKISYKC (SEQ ID NO: 15 2) Brevinin 1 FLPVLAGIAAKVVPALFCKITKKC (SEQ ID NO: 3) 20 Brevinin 1E FLPLLAGLAANFLPKIFCKITRKC (SEQ ID NO: 4) Peptide Al FLPAIAGILSQLF (SEQ ID NO: 5) 25 Peptide B9 FLPLIAGLLGKLF (SEQ ID NO: 6) To date, no antibacterial peptides have been isolated from the adult American bullfrog and studies of immature bullfrogs have indicated the presence 30 of only one antibacterial peptide, ranalexin having the sequence: FLGGLIKIVPAMICAVTKKC (SEQ ID NO: 7). The present invention has as its goal the isolation and characterization of amphibian antimicrobial peptides to assess their value as taxonomic and phylogenetic markers. A further goal of the present invention is the study of 35 seven different classes of Anuran peptides with antimicrobial activity which are obtained from extracts of the skins of six closely related species of North 4 WO 00/09553 PCTIUS99/18575 American frogs of the genus Rana: the spotted frog R. luteiventris, the Rio Grande leopard frog R. berlandieri,_green frog R. clamitans, the pig frog R. grylio. and the northern leopard frog R. pipiens and the North American bullfrog, R catesbeiana. 5 Summary of the Invention These and other objects are achieved by the present invention which is directed to seven families of peptides obtained from North American frogs (families of Rana peptides), to purified Rana compositions containing these peptides, to purified antibacterial extracts from Rana skin, to modified Rana 10 peptides, to truncated Rana peptides, to pharmaceutical compositions containing Rana peptides or modified forms thereof, and to methods for treatment of bacterial infections using Rana peptides or modified forms thereof. In particular, the invention is directed to seven families of Rana peptides shown below in Table 1. These Rana peptides have antibacterial activity and are 15 selected from any of the following seven peptide families. The Rana peptides may be in the form of their C-terminus carboxylic acids, or modified as C terminus amides or C-terminus esters. The amides may be a simple amide (CONH2), which is the isolated form for the Temporin-A and -B Families, or amides derived from Cl to C10 primary, secondary or tertiary aliphatic or 20 aromatic amines. The esters (COOR wherein the R group is the alcohol residue) are derived from C1 to C10 aliphatic or aromatic alcohols. The preferred C terminus forms for the Temporin-A and Temporin-B families are the simple aides. In these formulas, the single letters designate amino acid residues 25 according to accepted convention except that in the formulas for the peptides designated with a Family name followed by the term "mod", the letters X, B, Z, U, 0, J' and J, which are not conventional single letter designations of amino acid residues, are used as symbols to indicate a substitution of either any of the amino acid residues occurring at the same position within the other peptides of 5 WO 00/09553 PCTIUS99/18575 the same family or a conservative substitution of an amino acid residue for the amino acid substitution of an amino acid residue at the same position for any of the peptides within the same family of peptides. These symbols for the Family mod formulas have two identifiers: first is the identity of the symbol itself (X, B, 5 Z, U, 0, J' or J); second is the location/position of the symbol within the formula. For example, X of the Ranatuerin-1 mod appears at the 3, 16 and 21 positions of the formula. At each of these positions, X has a different meaning depending upon the corresponding amino acid residues at the same position of the other members of the family. In the case of the Ranatuerin-1 mod formula, 10 the X means that at the 3 position, the amino acid residue can be L, I or a conservative substitution therefor, at the 16 position the amino acid residue can be L, F or a conservative substitution therefor, and at the 21 position the amino acid residue can be I, V or a conservative substitution therefor. The term conservative substitution means substitution of an amino acid 15 residue by another that has the same side chain ionicity, basicity, acidity, lipophilicity or hydrogen bonding character as the residue being replaced. Examples include isoleucine (I), leucine (L), alanine (A), valine (V), phenyl analine (F), proline (P) and glycine (G) as an interchangeable group; lysine (K), histidine (H) and arginine (R) as an interchangeable group, seine (S), tyrosine 20 (Y) and threonine (T) as an interchangeable group; cysteine (C) and methionine (M)as an interchangeable group asparagine (N), glutamine (Q) and tryptophan (W) as an interchangeable group, and aspartic acid (D) and glutamic acid (E) as an interchangeable group. The letters after these amino acids are their single letter symbols. 25 The dashes in the ranatuerin-2 family peptides provide alignment of homologous peptide residues. The single and multiple dashes indicate a bond between the two amino acid residues on either side of the space occupied by the dashes. For the purpose of determining amino acid substitutions for this family, each dashed line constitutes a spacer instead of an amino acid residue. For 30 example, the 5 dashed lines of Ranatuerin-2 stand in the place of 5 amino acid 6 WO 00/09553 PCT/US99/18575 residues so that the A residue following the dashed lines is counted in the 19' position for the purpose of placing the amino acid residues of the individual peptides of the family into homologous alignment. Likewise, the 4 and 8 dashed lines of the Ranatuerin-2Ca and Ranatuerin-2Cb peptides respectively place the 5 A residue following those lines into the 19' position. TABLE 1 Families of Rana Peptides Ranatuerin-J family 10 Ranatuerin-1 SMLSVLKNLGKVGLGLVACKINKQC (SEQ ID NO: 8) Ranatuerin-IG SMISVLKNLGKVGLGFVACKVNKQC (SEQ ID NO: 9) Ranatuerin-IC SMLSVLKNLGKVGLGLVACKINKQC (SEQ ID NO: 10) 15 Ranatuerin-1 mod SMXSVLKNLGKVGLGXVACKXNKQC (SEQ ID NO: 11) Ranatuerin-2 family 20 Ranatuerin-2 GLFLDTLKGAAKD-AGK-LEGLKCKITGCKLP (SEQ ID NO: 12) Ranatuerin-3 GFL-DIKNLGKTF----AGHMLDKJKCTIGTCPPSP (SEQ ID NO: 13) Ranatuerin-2P GLM-DTVKNVAKNL----AGHMLDKLKCKITGC (SEQ ID NO: 14) 25 Ranatuerin-2B GLL-DTIKGVA----AASMLDKLKCKISGC (SEQ ID NO: 15) Ranatuerin-2Ca GLFLDTLKGAAKDV----AGKLLEGLKGKIAGCKP (SEQ ID NO: 16) Ranatuerin-2Cb GLFLDTLKGL- AGKLLQGLKCIKAGCKP (SEQ ID NO: 17) Ranatuerin-2La GI-LDSFKGVAKGVAKDLAGKLLDKLK GC (SEQ ID NO: 18) 30 Ranatuerin-2Lb GILSSI-KGVAKGVAKNVAAQLLDTLKCKITGC (SEQ ID NO: 19) Ranatuerin-2G GLLLDTLKGAAKDI----AGIALEKLKCKITGCKP (SEQ ID NO: 20) Ranatuerin-2 mod GBBBBBBKBBBBBBBBBBABBBBBBBKCBBBBGBBB (SEQ ID NO: 21) Esculentin-2 family 35 Esculentin-2L GILSLFTGGIKLGKTLFKMAGKAGAEHLACKATNQC (SEQ ID NO: 22) Esculentin-2B GLFSILRGAAKFASKGLGKDLTKLGVDLVACKIsKQC (SEQ ID NO: 23) 40 Esculentin-2P GFSSIFRGVAKFASKGLGKDLARLGVNLVACKISKQC (SEQ ID NO: 24) Esculentin-2 mod GZZSZZZGZZKZZZKZLZKZZZZZGZZZZAGKZZZQC (SEQ ID NO: 25) 45 Brevinin-F fam(iI Ranatuerin-4 FLPFIARLAAKVFPSCSVTKKC (SEQ ID NO: 26) 7 WO 00/09553 PCTIUS99/18575 Brevinin-lLa FLPMLAGLAASMVPKLVCLITKKC (SEQ ID NO: 27) Brevinin-lLb FLPMLAGLAASMVPKFVCLITKKC (SEQ ID NO: 28) 5 Brevinin-lBa FLPAIAGMAAKFLPKIFCAISKKC (SEQ ID NO: 29) Brevinin-lBb FLPAIAGMAAKFLPKIFCAISKKC (SEQ ID NO: 30) Brevinin-lBc FLPFIAGVAAKFLPKIFCAISKKC (SEQ ID NO: 10 31) Brevinin-lBd FLPAIAGVAAKFLPKIFCAISKKC (SEQ ID NO: 32) Brevinin-IBe FLPAIVGAAAKFLPKIFCVISKKC (SEQ ID NO: 33) 15 Brevinin-lBf FLPFIAGMAANFLPKIFCAISKKC (SEQ ID NO: 34) Brevinin-IPa FLPIIAGVAAKVFPKIFCAISKKC (SEQ ID NO: 35) Brevinin-lPb FLPIIAGLAAKVFPKIFCAISKKC (SEQ ID NO: 20 36) Brevinin-lPc FLPIIASVAAKVFSKIFCAISKKC (SEQ ID NO: 37) Brevinin-lPd FLPIIASVAANVFSKIFCAISKKC (SEQ ID NO: 38) 25 Brevinin-lPe FLPIIASVAAKVFPKIFCAISKKC (SEQ ID NO: 39) Brevinin-1 mod FLPUIUGUAAUUUPUUUCUIUKKC (SEQ ID NO: 40) 30 Ranalexin family Ranalexin-1 GFLGGLMKAFPALICAVTKKC (SEQ ID NO: 41) Ranalexin-1 CFLGGLMKIIPAAFCAVTKKC (SEQ ID 35 NO:42) Ranalexin-1 mod FLGGLMKJ'J'PAJ'J'CAVTKKC (SEQ ID NO: 43) Temp orin A family as the C-terminus carboxamide 40 Ranatuerin 5 FLPIASLLGKYL (SEQ ID NO: 44) Ranatuerin 6 FISAIASMLGKFL (SEQ ID NO: 45) Ranatuerin 7 FLSAIASMLGKFL (SEQ ID NO: 46) Ranatuerin 8 FISAIASFLGKFL (SEQ ID NO: 47) 45 Ranatuerin 9 FLFPLITSFLSKVL (SEQ ID NO: 48) Temporin-lCa FLPFLATLLSKVL (SEQ ID NO: 49) Temporin-lCb FLPFLAKILTGVL (SEQ ID NO: 50) Temporin-lCc FLPLFASLIGKKL (SEQ ID NO: 51) Temporin-lPa FLPIVGKLLSGLL (SEQ ED NO: 52) 50 Temporin-lLc FLPILINLIHKGL (SEQ ID NO: 53) Temporin-A mod FOOOOOOOOOOOLO (SEQ ID NO: 54) Temporin B Family as the C-terminus carboxamide 55 8 WO 00/09553 PCT/US99/18575 Temporin-ILa VLPLISMALGKLL (SEQ ID NO: 55) Temporin-lLb NFLGTLINLAKKIM (SEQ ID NO: 56) Temporin-IGa SILPTIVSFLSKFV (SEQ ID NO: 57) Temporin-lGb SILPTIVSFLSKFL (SEQ ID NO: 58) 5 Temporin-lGc SILPTIVSFLTKFIL (SEQ ID NO: 59) Temporin-lGd FIIPLIASFLSKFIL (SEQ ID NO: 60) Temporin-B mod JJJJJIJSFLJKJJL (SEQ ID NO: 61) 10 The purified compositions of the invention includes any composition containing one or more of the foregoing peptides obtained from a natural source such as Rana skin or obtained from a synthetic source. The modified Rana peptides of the invention include any of the foregoing Rana peptides designated as Ranatuerin-1 mod, Ranatuerin-2 mod, Esculentin-2 15 mod, Brevinin-1 mod, Brevinin-2 mod, Temporin-A mod and Temporin-B mod wherein the symbols X, B, Z, U, 0, P and J indicate substitutions of amino acid residues as discussed above. The modified Rana peptides of the invention also include the C-terminus amides and esters described above, which are derived from CI to C10 aliphatic or aromatic amines or alcohols. Further modified Rana 20 peptides include those wherein one or more of the amino acid residues valine (V), alanine (A), lysine (K), and glutamic acid (E) are substituted for the glycine (G) residues. Further modified Rana peptides of the invention include any of the foregoing Rana peptides wherein arginine (R) is substituted for one or more of the lysine (K) residues. 25 Additional modified Rana peptides contain modified side chains so that any of the Rana peptides with amino acid residues having functionalized side chains can be modified with amidation or esterification groups. Examples include those in which the epsilon amino group of a lysine (K) residue has been coupled to a C, 0 to C 20 fatty acid such a palmitate or glycosylated sugar, those in 30 which the epsilon carboxy group of aspartic (D) or glutamic (E) acid residues or hydrolyzed glutamine (Q) residue have been coupled to fatty alcohols or glycosylated sugars, or those in which the epsilon hydroxyl group of threonine (T), tyrosine (Y), or serine (S) residues have been coupled to fatty acids or glycosylated sugars. In particular, ranatuerin 1 having any of these side chain 9 WO 00/09553 PCTIUS99/18575 modifications, where the appropriate amino acid residue is present, is preferred. In addition, the modified Rana peptides include those in which a truncated fragment is synthetically condensed with a non-natural peptide or peptide sequence optionally containing heterocyclic organic moieties such as a beta or 5 gamma amino acid, an aliphatic diamine, an aliphatic or aromatic dicarboxylic acid, pyridine carboxylic acid, aromatic diols and the like. The truncated versions of Rana peptides include the fragments formed by cleaving at any of the glycine residues or between any repeat residues, and fragments formed by N-terminal deletion of pairs of amino acid residues. 10 Further truncated versions include those that are cleaved at the single or multiple dash symbols. For example, truncated versions of ranatuerin 1 include those containing amino acid residues 1-9, the fragment containing amino acid residues 16 - 25, N-terminally deleted fragments such as ranatuerin 1 (3-25), (5-25), (7 25), (9-25), (11-25), (13-25), (15-25), (17-25) and (19-25). 15 The pharmaceutical composition of the invention includes the combination of one or more Rana peptides with a pharmaceutical carrier rendering the composition suitable for an appropriate route of administration to a patient. The method of treatment of the invention involves administration of an 20 effective amount of the pharmaceutical composition by an appropriate route to a patient suffering from a target bacterial infection. Brief Description of the Drawings FIG. 1 presents a graph of a gel permeation chromatography of an extract 25 of the skin of Rana luteiventris. FIGS. 2A, B present graphs of a reverse-phase HPLC of the antimicrobial activity of R. luteiventris skin. FIGS. 3A, B present graphs of the chromatographic results of a partial purification of the fractions from R. luteiventris skin having antimicrobial 30 activity. 10 WO 00/09553 PCTIUS99/18575 FIGS. 4A, B and C present graphs of the chromatographic results of a purification of ranatuerin 2La, ranatuerin 2Lb and esculentin 2L. FIG. 5 presents gel permeation chromatography on Sephadex G-25 of an extract of the skin of Rana catesbeiana after partial purification on Sep-Pak 5 cartridges. The fractions in zone A contained ranatuerins 1-5 and the fractions in zone B contained ranatuerins 6-9. FIGS. 6A and 6B present reversed-phase HPLC on a semipreparative Vydac C-18 column. FIG. 6A presents the pooled fractions from zone A in Fig. 5 and Fig. 6B presents the pooled fractions from zone B in FIG. 5. The dashed 10 line shows the concentration of acetronitrile in the eluting solvent and the bars show the fractions containing the ranatuerins indicated. Detailed Description of the Invention The present invention is directed to a systematic investigation of extracts of the skin of adult Ranid frogs and characterization of all the peptides with 15 inhibitory activity towards bacteria. The skins of frogs of the genus Rana produce a diverse array of peptides with antimicrobial activity. A comparison of the amino acid sequences of these peptides demonstrates that they may be arranged in families on the basis of structural similarity. Attempts to catalogue the antimicrobial peptides are hampered by the absence of a systematic 20 terminology and by the fact that peptides clearly belonging to the same structurally family have been given different names. As shown in Table 1, Summary of the Invention, at least 7 different peptide families produced in the skins of Ranid frogs have been identified on the basis of amino acid sequence similarity. For the present invention, these families are named from the first 25 member to have been discovered as follows: (1) ranatuerin-1, (2) ranatuerin-2 which includes ranatuerin-3, (3) brevinin-1 which includes gaegurin-5 and -6, and ranatuerin-4, (4) brevinin-2 which includes rugosin A, and B and ranatuerin IT, (5) esculentin-2 which includes gaegurin-1, -2, -3 and -4 and rugosin C, (6) ranalexin and (7) temporin which includes peptides Al and B9 and ranatuerins 30 5, -6, -7, -8 and -9. 11 WO 00/09553 PCT/US99/18575 The C-terminal region of peptides of the brevinin-1, ranalexin, brevinin 2, esculentin- 1, esculentin-2 and ranatuerin- 1 families contains a cystine-bridged cyclic lieptapeptide whereas the corresponding region of peptides of the ranatuerin-2 family contains a cystine-bridged cyclic hexapeptide. The temporin 5 family peptides lack the cyclic region and their primary structures have been poorly conserved. All members of the family contain between 10-14 amino acid residues and terminate in a C-terminally (a-amidated amino acid residue. The present invention establishes that extracts of the skins of six closely related North American frogs of the genus Rana contain antimicrobial peptides 10 belonging to 5 of the known families: brevinin-1, ranatuerin-2, esculentin-2, ranalexin and temporin. These peptides classified by using the initial letter of the species name to indicate their origin (L for luteiventris, B for berlandieri and P for pipiens, C for clamitans and G for grylio. The catesbeiana peptides are regarded as the "parent" and so are not given a letter.) Where two or more 15 members of the same family are produced by the one species, the peptides are differentiated by the letters a, b, c, etc. as in the examples of ranatuerin-2La and ranatuerin-2Lb. The distribution of the molecular forms of the biological active peptides and the primary structures of the individual peptides are highly species-specific. 20 Each frog in this study produced multiple peptides of the brevinin-1 family and at least one peptide of the esculetin-2 and ranatuerin-2 families but a peptide of the temporin family was not detected in R. berlandieri skin despite a systematic search for such a component. Similarly, peptides that are structurally related to ranalexin and ranatuerin-1, previously isolated from the North American 25 bullfrog, R. catesbeiana, were not identified in the skin extracts of the other species. At this time, peptides belonging to the esculentin-1 and brevinin-2 families have not been identified in the skins of North American Ranid frogs. None of the antimicrobial peptides isolated in this study have been described previously. 12 WO 00/09553 PCT/US99/18575 It has been proposed that the synthesis of multiple structurally related peptides by the skin of an amphibian species serves to protect the organism against invasion by a broad array of microorganisms because each peptide has a discrete spectrum of antimicrobial activity and may target specific bacteria. The 5 peptides of the brevinin-1, esculentin-2 and ranatuerin-2 families isolated in the present study show a broad spectrum of antimicrobial activity inhibiting the growth of a gram positive bacterium (Staphylococcus aureus), a gram negative bacterium (Escherichia coli) and a yeast (Candida albicans). However, of the microorganisms tested, the peptides of the temporin family were active only 10 against S. aureus. As shown in Table 1, Summary of the Invention, ranatuerin 4 contains limited structural similarity, including the presence of a C-terminal heptapeptide ring, to the previously characterized gaegurins (Park, J.M., Jung, J.E., and Lee, B.J., Biochem. Biophys. Res. Commun. 205, 948-954 (1994)); and brevinins 15 (Morikawa, N., Hagiwara, K., and Nakajima, T., Biochem. Biophys. Res. Commun. 189, 184-190 (1992); Simmaco, M., Mignogna, G., Barra, D., and Bossa, F., J. Bio. Chem. 269, 11956-11961 (1994)) also isolated from the skin of other Ranid frogs. Ranatuerins 5 - 9 show some sequence identity to the hemolytic peptides Al and B9 previously isolated from the skin of Rana 20 esculenta (Simmaco, M., De Biase, D., Severinin, C., Aita, M., Falconieri Erspamer, G., Barra, D., and Bossa, F., Biochim. Biophys. Acta 1033, 318-323 (1990)). Ranatuerins 1, 2, and 3, however, do not resemble closely any other anti-microbial peptides isolated from amphibian skin. The amino acid sequence motif C-K-[V/I/L]-[A/S/T]-K-[K/T/Q]-C, 25 asserted for all antimicrobial peptides from species of the genus Rana without exception (Park, J.M., Jung, J.E., and Lee, B.J., Biochem. Biophys. Res. Commun. 205, 948-954 (1994)), is absent from the many of the Rana peptides of the present invention. A further unexpected feature of the present invention is that ranalexin, previously isolated from an extract of whole bullfrog tadpoles 30 (Clark, D.P., Durell, S., Maloy, W.L., and Zasloff, M., J. Bio. Chem. 269, 13 WO 00/09553 PCT/US99/18575 10849-10855 (1994)), is not present among the ranatuerins. Since ranalexin shows potent cytolytic activity towards S. aureus (minimal inhibitory concentration of 4 pg/ml), it would not have been missed during the investigation of the bullfrog skin extracts. It is probable, therefore, that the 5 expression of the antimicrobial peptides in bullfrog skin is developmentally regulated. Many of the Rana peptides show high potency and a broad spectrum of antimicrobial properties against the gram positive, gram negative bacteria and against the fungi, see the tables and figures. Thus, the amino acid sequence of 10 the potent Rana peptides can also form the basis for modified versions exhibiting higher potency and with specificity towards pathogenic microorganisms that have developed resistance to commonly used antibiotics. In particular, one modification focuses upon the presence of a cystine bridge at the C-terminal end of the brevinin-1, ranalexin, brevinin-2, esculentin 15 1, esculentin-2 and ranatuerin-1 families and the ranatuerin-2 family. Synthesis of modified Rana peptides containing the substitutions Cys -+ Ala and Cys -> Ser provides peptides that will have no cysteine bridges. These modified Rana peptides will show inhibitor activity against Escherichia coli, Staphylococcus aureus and Candida albicans. 20 In general, other modified ranatuerins can be formulated through an understanding of the mechanism by which antimicrobial peptides are cytotoxic. Antimicrobial peptides such as the Rana peptides have a propensity to form amphipathic a-helical structures and their mechanism of action is believed to involve a direct interaction with the fatty acyl chains in the cell membrane 25 leading to disruption of normal membrane function responsible for osmotic balance. The presence of cationic residues (particularly lysine) in antimicrobial peptides is believed to destroy the ionic gradient across cell membranes by forming ion channels. Cruciani, R.A., Barker, J.L., Durell, S.R., Raghunathan, G., Guy, H., Zasloff, M., and Stanley, F., Eur. J. Pharmacol. 226, 287-296 30 (1992). Analysis of the secondary structure of a Rana peptide, either by the 14 WO 00/09553 PCT/US99/18575 method of Gamier, Osguthorpe and Robson or by the method of Qian and Sejnowski, predicts that most of the peptides contain two a-helical regions joined by a glycine-containing "hinge" region. Gamier, J., Osguthorpe, D., and Robson, B., JMol. Bio. 120, 97-121 (1978); Qian, N., and Sejnowski, T., J. 5 Mo. Biol. 202, 865-884 (1988)). This conformation is, for example, found in the cecropin family of antimicrobial peptides isolated from insect hemolymph and from mammalian intestine. Gamier, Osguthorpe and Robson 10 SMLSVLKNLGKVGLGFVACKINKQC (SEQ ID NO: 62) AAAAAAA-TBBBBBBBAAATIT E Qian and Sejnowski 15 SMLSVLKNLGKVGLGFVACKINKQC (SEQ ID NO: 63)

--AAAAA-----AAAA--

A a-helix; B p-sheet; T p-turn; - random coil 20 Based upon this understanding, one generation of modified Rana peptides is constructed by substituting one or more of the a-helix-extending residues (hydrogen bonding residues) for the lipophilic amino acid residues within the helix regions of an individual Rana peptide, especially those within the C 25 terminus region of the peptides. Other amino acid residues can be substituted as follows: (a) Ala is substituted for Gly in order to replace the p-sheet region in the central portion of the peptide with an extended a-helix. The increased a-helical character of the peptide promotes interaction with the cell 30 membrane of the targeted microorganism; (b) Val is substituted for Gly in order to stabilize the p-sheet region in the central portion of the peptide; (c) Ala or another lipophilic amino acid residue is substituted for Asn in order to promote a-helical character; 15 WO 00/09553 PCTIUS99/18575 (d) Glu is substituted for Gly in order to promote a-helical character. Modified Rana peptides also include those Rana peptide Family modified peptides with the formulas containing the symbols X, B, Z, U, 0, J' and J as 5 discussed in the Summary of the Invention. Still further modified Rana peptides can also prepared by substituting one or more of the lysine residues by arginine. This substitution will increase the cationic character of the peptide so as to promote its ability to affect the cellular membrane ionic gradient. 10 Another generation of modified Rana peptides includes truncated Rana peptides lacking redundant segments of the original molecules, and protease resistant modified Rana peptides containing D-amino acid residues and/or unnatural amino acids and/or side chain modified amino acids. The Rana peptides can also be modified by substitution of one or more of the amino acid 15 residues valine (V), alanine (A), lysine (K), and glutamic acid (E) for the glycine (G) residues. Further modified Rana peptides include those wherein arginine (R) is substituted for one or more of the lysine (K) residues. The truncated versions of Rana peptides include the fragments cleaved on the N side of the any of the glycine residues or between repeat residues as well as N-terminally deleted 20 fragments. Any of the Rana peptides can be modified with amino acid residues having modified side chains such as those in which the epsilon amino group of a lysine (K) residue has been coupled to a fatty acid such a palmitate or glycosylated sugar, those in which the epsilon carboxy group of aspartic (D) or glutamic (E) acid residues or a hydrolyzed glutamine (Q) residue have been 25 coupled to fatty alcohols or glycosylated sugars, or those in which the epsilon hydroxyl group of threonine (T), tyrosine (Y), or seine (S) residues have been coupled to fatty acids or glycosylated sugars. In addition, the modified Rana peptides include those in which a truncated version is synthetically condensed with a non-natural peptide or peptide sequence optionally containing 30 heterocyclic organic moieties such as a beta or gamma amino acid, an aliphatic 16 WO 00/09553 PCT/US99/18575 diamine, an aliphatic or aromatic dicarboxylic acid, pyridine carboxylic acid, aromatic diols and the like. The Rana peptides and modified versions can be obtained by automated peptide synthesis using such techniques as the "Merrifeld" technique, the 5 recombinant DNA techniques involving insertion, expression and isolation, and by extraction techniques from any source in nature (for naturally occurring Rana peptides). In addition, semi-synthetic Rana peptides can be obtained by preparation of the peptide sequence using any of the foregoing techniques and coupling the peptide sequence to the chemical moiety by esterification, 10 amidation, Schiff base formation under appropriate side chain protection if needed. These techniques are well known in the art. For example, a Merrifeld technique is described in US Patent No. 5,049,656, the disclosure of which is incorporated herein by reference, and a recombinant technique is described at U.S. Patent Nos. 4,237,224 and 5,595,887, the disclosures of which are 15 incorporated herein by reference. Semisynthetic coupling techniques as well as amidation and esterification of carboxylic acids (eg., for the formation of the C terminus amides and esters) are described in "Advanced Organic Chemistry", J. March, Wiley Interscience 4th Ed., 1992. An example of an extraction technique is set forth in the following experimental example. 20 In regard to the recombinant techniques, the Rana peptides are present in Ranid frog skin in very high abundance and so it is not envisaged that cloning of the cDNAs encoding the peptides will present a particularly difficult challenge. Standard cloning techniques can be used. Poly(A)-rich RNA from bullfrog skin can be prepared by affinity chromatography and a constructed cDNA library. A 25 pool of mixed nucleotides encoding appropriate regions of the Rana peptide DNA sequence such as the 19-25 region of ranatuerin 1 or analogous regions of the other Rana peptide DNA sequences can be synthesized for use as a primer in the RACE (rapid amplification of cDNA 3' end) protocol using the polymerase chain reaction. Amplification products can be cloned into the XhoI/EcoRV 30 restriction site of the BlueScript vector (Stratagene). The clone can be labeled 17 WO 00/09553 PCT/US99/18575 by random priming and then used to screen the cDNA to obtain a full-length clone. Positive clones can be selected and analyzed by nucleotide sequencing. This approach has been used successfully to clone the cDNAs encoding esculentin and brevinin 1E from the frog Rana esculenta (J. Biol. Chem. 5 269:11956-11961, 1994). The cDNA clone containing the genome for ranatuerin or a modified version thereof can be expressed by known recombinant techniques such as by insertion and expression in E Coli. Since the Rana peptides are antimicrobial, a preferred technique will involve triggering the culture to express after it has reached maturity. 10 For effective prophylactic and anti-infectious use, the Rana peptides and their modified and truncated forms as well as the compositions of the present invention may be administered either alone or in combination with a pharmaceutically-acceptable carrier, by topical, oral, anal, ocular, buccal, nasal, intramuscular, subcutaneous, intravenous, or parenteral routes. The ultimate 15 choice of route, formulation and dose is made by the attending physician or veterinarian and is based upon the patient's or animal's unique condition. However, the usual dosage for administration to humans lies in the range of approximately 50-2000 mg. P.O. per day, and preferably in about one to four doses where the dose is based upon the activity of pure Rana peptide. The usual 20 dosage for administration to small animals lies in the same approximate range as that for humans. For large animals, the usual dosage is higher per unit of body weight so that the dose given lies in the range of about 20 to 20,000 mg. P.O. per day. This dosage may vary somewhat with the weight of the subject (human or animal) being treated; in general, about 1-40 mg./kg. of body weight per day can 25 be employed for humans and small animals while about 1 to 400 mg./kg. of body weight per day can be employed for large animals. The Rana peptides of this invention can be combined with inert pharmaceutical excipients such as lactose, oil, mannitol and starch, and formulated into dosage forms such as elixirs, liquids, ointments, lotions, IV 30 fluids, alcohol, tablets, capsules, and the like. For parenteral, intramuscular, 18 WO 00/09553 PCT/US99/18575 subcutaneous and intravenous administration, these peptides can be formulated with an inert, parenterally acceptable vehicle such as water, saline, sesame oil, ethanol buffered aqueous medium, propylene glycol and the like. For topical and oral administration, these peptides can be formulated with waxes, oils, 5 buffered aqueous medium, and the like. These various pharmaceutical dosage forms are compounded by methods well known to the pharmacist's art. Following the foregoing regimen, the antibacterial activity of the Rana peptides as well as the modified and truncated forms thereof likely will show inhibition action against the following strains of bacteria and fungi. 10 1. Escherichia coli Drug-resistant strains of this "harmless" organism are responsible for twice as many cases of nosocomial infections as any other microbe, particularly hospital-acquired urinary tract infections. 15 2. Enterococcus sp. These organisms are responsible for infection of wounds especially in elderly patients undergoing surgery. E. faecalis is also responsible for urinary tract infections and frequently invades heart valves and prosthetic devices of 20 hospitalized patients. 3. Bactereoidesfragilis Although this Gram-Negative anaerobe is a component of the normal flora of the gut, resistant strains are responsible for wound and abdominal 25 infections in hospitalized patients. 4. Pseudomonas aeruginosa Infections that may lead to septicemia and pneumonia, are especially common in burn patients. The organism is frequently introduced into body 19 WO 00/09553 PCT/US99/18575 orifices by contaminated catheters and other invasive instruments and proliferates in respirators and renal dialysis units 5. Klebsiella pneumoniae 5 The organism readily grows in glucose solutions used for intravenous therapy leading to deaths from bacteremia. Pneumonia caused by Klebsiella has a 50% mortality rate in spite of treatment with existing antibiotics. 6. Serratia marcescens 10 Like Klebsiella, this Gram-Negative organism grows in glucose solutions and infection leads to colonization of the oropharynx of chronically ill persons leading to pneumonia. , 7. Mycobacterium tuberculosis 15 Since 1985, the incidence of tuberculosis has dramatically increased in the U.S.A. due to the emergence of strains resistant to Isoniazid and Rifampin, the major drugs used in treatment. Hospital epidemics in AIDS and other immunosuppressed patients are common. 20 8. Streptococcus pneumoniae The organism is responsible for 80% of all bacterial pneumonias and is particularly prevalent in institutions housing old people such as nursing homes and geriatric wards. In young people infection of the middle ear leads to meningitis and otitis media. 25 9. Streptococcus pyrogenes The organism responsible for "strep throat" which, if improperly treated, can lead to complications of rheumatic heart disease, pneumonia and glomerulonephritis. 30 20 WO 00/09553 PCT/US99/18575 10. Haemophilus influenzae This pathogen is responsible for the increasing incidence of acute bacterial meningitis in children and is often transmitted in day-care settings. Even with prompt diagnosis and aggressive treatment with existing antibiotics, 5 33% of children sustain residual disability. 11. Staphylococcus saprophyticus Staphylococcus sp. in hospitals is generally antibiotic resistant and poses a particular problem in nurseries, delivery rooms and burn units. S. 10 saprophyticus causes urinary-tract infections particularly in sexually active young women and in immunosuppressed patients. 12. Candida albicans Antibiotic therapy or severe immunosuppression often precedes 15 extensive invasion by C. albicans and is particularly common in burn patients and in recipients of renal, heart and bone marrow transplants. The following experimental examples further illustrate the invention. They are not meant to provide limitations of the invention that has been fully 20 characterized by the foregoing discussion. The foregoing specification, examples and data provide a complete description of the preparation and use of the composition of the invention. Since many embodiments of the invention can be made without departing from the spirit and scope of the invention, the invention resides in the claims hereinafter appended. 25 MATERIALS AND METHODS Taxonomic identification of individual specimens of frogs of the genus Rana is often difficult especially in regions where several species coexist and produce hybrids. Similarly, the phylogenetic interrelationships between the 30 different species are incompletely understood. It is suggested, therefore, that 21 WO 00/09553 PCT/US99/18575 study of the distribution and amino acid sequences of antimicrobial peptides in skin may prove to be a valuable tool for the identification and taxonomic classification of Ranid frogs. Once a larger data set of primary structures has been compiled, the amino acid sequences may form a basis for cladistic analysis 5 to investigate phylogenetic interrelationships between species. Skin secretions, containing very high concentrations of antimicrobial peptides, can easily be collected from Ranid frogs by non-invasive procedures (mild electrical stimulation or subcutaneous injection of epinephrine) so that identification of the species does not necessitate sacrifice of the animal. Molecular techniques have 10 been used previously to facilitate identification and to study phylogenetic relationships among Ranid frogs. For example, analysis of the nucleotide sequences of mitochondrial and genomic DNA has been used to investigate the evolutionary history of specimens of the closely related species of European water frogs, R. ridibunda, R. esculenta and R. lessonae. 15 Animals Adult specimens of both sexes of the spotted frog, R. luteiventris (n= 16; wt range 12 - 40 g), the Rio Grande leopard frog, R. berlandieri (n = 8; wt range 51 - 115 g), the North American bull frog R. catesbeiana, R. clamitans (n=21; wt 20 range 44-75 g), R. grylio (n=6; wt range 106-204g) and the northern leopard frog, R. pipiens (n = 12; wt range 41 - 54 g) were purchased from Charles D. Sullivan Company (Nashville, TN, U.S.A.). The animals were anaesthetized by immersion in crushed ice and were sacrificed by pithing. Skin was immediately removed, frozen on dry ice and stored at -55*C until time of extraction. 25 Tissue Extraction The frozen skins (R. luteiventris 45 g; R. berlandieri 66 g; R. clamitans 125g; R. grylio; 96 g; R. pipiens 58 g) were separately extracted by homogenization in ethanol/0.7 M HCl (3:1 v/v; 10 ml/g ) at 0*C using a Waring 30 blender. The homogenates were stirred for 2 h at 0*C and centrifuged (4000 x g 22 WO 00/09553 PCT/US99/18575 for 30 min at 4"C). Ethanol was removed from the supernatants under reduced pressure and, after further centrifugation (4000 x g for 30 min at 4"C), the extracts were separately pumped onto 8 Sep-Pak C-18 cartridges (Waters Associates, Milford, MA, U.S.A.) connected in series at a flow rate of 2 ml/min. 5 Bound material was eluted with acetonitrile/water/trifluoroacetic acid (70.0:29.9:0.1, v/v/v) and freeze-dried. For the R. catesbeiana the tissue extraction was as follows. Skin (176 g) was removed from pithed adult specimens of R. catesbeiana of both sexes (n = 6) and immediately frozen on dry-ice. The tissue was stored at -55 0 C until time 10 of extraction. The tissue was extracted by homogenization in ethanol/0.7 M HCl (3:1 v/v; 1800 ml) at 0 0 C using a Waring blender. The homogenate was stirred for 2 h at 0 *C and centrifuged (4000 x g for 30 min at 4 'C). Ethanol was removed from the supernatant under reduced pressure and, after further centrifugation (4000 x g for 30 min at 4 *C), the extract was pumped onto 8 Sep 15 Pak C-18 cartridges (Waters Associates) connected in series at a flow rate of 2 ml/min. Bound material was eluted with acetonitrile/ water/ trifluoroacetic acid ((70.0:29.9:0.1, v/v/v) and freeze-dried. Peptide Purification. 20 The same chromatographic procedures were used to purify antimicrobial peptides from each of the species R. luteiventris, R. berlandieri, R. clamitans, R. grylio and R. pipiens so only the methods used to isolate the R. luteiventris peptides will be described in detail. The skin extract, after partial purification on Sep-Pak cartridges, was redissolved in 1% (v/v) trifluoroacetic acid/water (5 ml) 25 and chromatographed on a (100 x 2.6 cm) column of Sephadex G-25 (Pharmacia Biotech, Uppsala, Sweden) equilibrated with 1 M acetic acid. The column was eluted at a flow rate of 48 ml/h and fractions (8 ml) were collected. Absorbance was measured at 280 nm. The ability of aliquots (50 pl) of the fractions to inhibit the growth of S. aureus was determined as described in the previous 30 section. Fractions containing maximum activity (denoted by the bars in Fig. 1) 23 WO 00/09553 PCTIUS99/18575 were pooled and injected onto a (25 x 1 cm) Vydac 218TP510 C-18 reverse phase HPLC column (Separations Group, Hesperia, CA, USA) equilibrated with 0.1% (v/v) trifluoroacetic acid/water at a flow rate of 2 ml/min. The concentration of acetonitrile in the eluting solvent was raised to 21% (v/v) over 5 10 min and to 49% (v/v) over 60 min using linear gradients. Absorbance was monitored at 214 nm and 280 nm and fractions (1 min) were collected. The fractions containing antimicrobial activity were successively rechromatographed on (250 x 4.6 mm) Vydac 214TP54 (C-4) and Vydac 219TP54 (phenyl) reverse phase HPLC columns. The concentration of acetonitrile in the eluting solvent 10 was raised from 21% to 55% over 40 min and the flow rate was 1.5 ml/min. The purification of the R. catesbeiana frog skin extract was accomplished in similar fashion. After partial purification on Sep-Pak cartridges, the extract was redissolved in 1% (v/v) trifluoroacetic acid/water (5 ml) and chromatographed on a (100 x 2.6 cm) column of Sephadex G-25 15 (Pharmacia Biotech) equilibrated with 1 M acetic acid. The column was eluted at a flow rate of 48 ml/h and fractions (8 ml) were collected. Absorbance was measured at 280 nm. The antimicrobial activity of aliquots of the fractions was determined. Fractions containing maximum activity (denoted by the bars in Fig. 1) were pooled and injected onto a (25 x 1 cm) Vydac 218TP510 C-18 reversed 20 phase HPLC column (Separations Group) equilibrated with 0.1% (v/v) trifluoroacetic acid/water at a flow rate of 2 ml/min. The concentration of acetonitrile in the eluting solvent was raised to 21% (v/v) over 10 min and to 49% (v/v) over 60 min using linear gradients. Absorbance was monitored at 214 nm and 280 nm and fractions (1 min) were collected. The fractions containing 25 antimicrobial activity were successively rechromatographed on (250 x 4.6 mm) Vydac 219TP54 (phenyl) and Vydac 208TP54 (C-8) columns. The concentration of acetonitrile in the eluting solvent was raised from 14% to 35% over 40 min and the flow rate was 1.5 ml/min. 30 24 WO 00/09553 PCTIUS99/18575 Separation of R. luteiventris peptides The peptide fractions in the extract of R. luteiventris skin showing growth-inhibiting activity against S. aureus, after partial purification on Sep-Pak cartridges, were eluted from a Sephadex G-25 gel permeation column as two 5 discrete zones, designated by the bars in Fig. 1. Subsequent characterization studies demonstrated that zone A contained esculentin-2L, ranatuerin-2La, and ranatuerin-2Lb and zone B contained brevinin-ILa, brevinin-1Lb, temporin-ILa, temporin-lLb and temporin-lLc. After chromatography of pooled fractions from zone A on a semipreparative Vydac C-18 reverse-phase HPLC column 10 (Fig. 2A), the antimicrobial activity was eluted in a single, but very broad region, of the chromatogram with retention time between 45 and 70 min. Chromatography of pooled fractions from zone B (Fig. 1) on the semipreparative C-18 column resulted in the elution of the antimicrobial activity in overlapping fractions with retention times between 48 an 75 min (Fig. 2B). 15 The same chromatographic procedures were used to purify all the biologically active peptides and so only the purification of those from zone A (Fig. 1) will be described in detail. Fractions with retention times between 45 and 55 min from the semipreparative C-18 column (Fig. 2A) were pooled and chromatographed on a Vydac C-4 column (Fig. 3A). Although resolution was 20 poor, antimicrobial activity (associated with ranatuerin 2La) was eluted in the fractions denoted by the bar. Fractions with retention times between 56 and 70 min from the C-18 column (Fig. 2A) were pooled and chromatographed on a Vydac C-4 column (Fig. 3B). Antimicrobial activity was eluted in two discrete zones denoted by the bars. The earlier eluting fractions contained ranatuerin- 25 2Lb and the later eluting fractions contained esculetin-2La. The antimicrobial peptides were purified to near homogeneity, as assessed by symmetrical peak shape, by a final chromatography on a Vydac phenyl column as shown in Figs. 4 (A- C). The final yields of pure peptides were: ranatuerin 2La, 4050 nmol; ranatuerin 2Lb, 320 nmol; and esculentin-2L, 740 nmol. 25 WO 00/09553 PCTIUS99/18575 Purification of antimicrobial peptide from zone B from gel permeation chromatography (Fig. 1) on Vydac C-4 and Vydac phenyl columns resulted in the isolation in pure form of brevinin-1La (880 nmol), brevinin-llb (45 nmol), temporin-ILa (120 nmol), temporin-lLb (200 nmol) and temporin-lLc (60 5 mnol). The final yields of the pure peptides are shown in parentheses. Separation of R. berlandieri, R. clamitans, R. grylio and R. pipiens peptides Using the same chromatographic procedures for separation of antimicrobial peptides from R. luteiventris led to the isolation in pure form of the 10 following peptides from R. berlandieri skin in the yields indicated: brevinin-1Ba (4 nmol), brevinin-lBb (15 nmol), brevinin-lBc (8 nmol), brevinin-lBd (28 nmol), brevinin-1Be (12 nmol), brevinin- lBf (9 nmol), esculentin-2B (31 nmol), and ranatuerin-2B (75 nmol). The following peptides with antimicrobial activity were isolated from R. pipiens skin in the yields indicated: brevinin-lPa (1050 15 nmol), brevinin-lPb (1110 nmol), brevinin-lPc (64 nmol), brevinin-lPd (315 nmol), brevinin-lPe (8 nmol), esculentin-2P (12 nmol), ranatuerin-2P (690 nmol), and temporin-1P (205 nmol). The following peptides were isolated from R. clamitans skin in the yields indicated: ranatuerin-1C (570nmol), ranalexin-1C (715 nmol), ranatuerin-2Ca (30 nmol), ranatuerin-2Cb (110 nmol), Temporin 20 1Ca (240 nmol), temporin-1Cb (qnm), temporin-1Cc (qnm). The following peptides were isolated from R. grylio skin in the yields indicated: ranalexin-IG (50 nmol), ranatuerin-1G (70 nmol), ranatuerin-2G (55 nmol), and temporin-1Ga (180 nmol). (qnm means quantity not measured.) 25 Separation of R. catesbeiana peptides The peptide fractions in the extract of R. catesbeiana skin, after partial purification on Sep-Pak cartridges, were eluted from a Sephadex G-25 gel permeation column as two zones (Fig. 5). After chromatography of pooled fractions from the earlier-eluting zone A on a semipreparative Vydac C-18 30 reversed-phase HPLC column, the activity was eluted in three non-overlapping 26 WO 00/09553 PCT/US99/18575 fractions that were subsequently shown to contain ranatuerins 1+ 5, ranatuerins 2+3 and ranatuerin 4 (Fig. 6A). Similarly, chromatography of pooled fraction from zone B led to the separation of activity into three fractions subsequently shown to contain ranatuerins 6+ 7, ranatuerin 8 and rantuerin 9 (Fig. 6B). The 5 peptides were purified to near homogeneity, as assessed by a symmetrical peak shape, by chromatography on analytical Vydac phenyl and C-8 columns. The approximate yields of pure peptides were: ranatuerin 1, 120 nmol; ranatuerin 2, 80 nmol; ranatuerin 3, 50 nmol; ranatuerin 4, 160 nmol; ranatuerin 5, 140 nmol; ranatuerin 6, 170 nmol; ranatuerin 7, 250 nmol; ranatuerin 8, 120 nmol and 10 ranatuerin 9, 400 nmol. Structural analysis. Amino acid compositions were determined by precolumn derivatization with 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate using a Waters AccQ 15 Tag system with fluorescence detection and separation of the amino acid derivatives by reverse-phase HPLC. Hydrolysis in 5.7 M HC1 (24 h at 1 10*C) of approximately 1 nmol of peptide was carried out. The primary structures of the peptides were determined by automated Edman degradation using an Applied Biosystems model 471 A sequenator modified for on-line detection of 20 phenylthiohydantoin amino acids under gradient elution conditions. Electrospray mass spectrometry was carried out using a Perkin Elmer Sciex API 150EX single quadrupole instrument. The accuracy of mass determinations was 0.02%. The primary structures of the peptides their amino acid sequences are 25 shown in Table 1, Summary of the Invention. In all cases, the proposed amino acid sequences, including the presence of a cystine bridge in the brevinin-1, esculentin-2 and ranatuerin-2 peptides were confirmed by amino acid composition analysis (data not shown) and mass spectrometry (Fig. 5). Mass spectrometry also demonstrated that the peptides of the temporin family 30 contained a C-terminally a-amidated residue. 27 WO 00/09553 PCTIUS99/18575 Antimicrobial assays Minimal inhibitory concentrations (MICs) of the peptides were determined by a standard microdilution method using 96-well microliter cell 5 culture plates as previously described. Serial dilutions of the peptides in Mueller-Hinton broth (50 pL) were incubated with an inoculum (50 pL of 10' CFU/mL) from an overnight culture of Escherichia coli (ATCC 25922) and Staphylococcus aureus (NCTC 8325), for 18 h at 37"C in an humidified atmosphere of 5% C0 2 in air. Incubations with Candida albicans (ATCC 90028) 10 were carried out in RPMI 1640 medium for 48 h at 35*C. After incubation, the absorbance at 550 nm of each well was determined using a M.A. Bioproducts model MA308 microliter plate reader. The MIC of each peptide was taken as the lowest concentration where no visible growth was observed. In order to monitor the validity of the assay, incubations with E. coli and S. aureus were carried out 15 in parallel with increasing concentrations of the broad-spectrum antibiotic, bacitracin and incubations with C albicans in parallel with amphotercin B. The abilities of the isolated peptides to inhibit the growth of the gram positive bacterium Staphylococcus aureus, the gram-negative bacterium Escherichia co/i and the yeast, Candida albicans are compared in Table 2 (NA 20 in Table 2 means no activity; ND means not determined.) Ranatuerins 1-9, tested at a concentration of 20 jg/ml, showed no detectable hemolytic activity towards human erythrocytes. TABLE 2 25 MIC (pM) S. aureus E. coli C. Albicans Rana catesbeiana Ranatuerin 1 50 2 70 Ranatuerin 2 60 60 NA 28 WO 00/09553 PCTIUS99/18575 Ranatuerin 3 60 70 NA Ranatuerin 4 55 ND NA Ranatuerin 5 >200 ND NA Ranatuerin 6 100 ND NA Ranatuerin 7 200 ND NA Ranatuerin 8 130 ND NA Ranatuerin 9 130 ND NA Rana luteiventris Brevinin-1Lb 8 16 ND Esculetin-2L 3 6 53 Ranatuerin-2La 11 4 >150 Ranatuerin-2Lb 4 4 62 Temporin-1La 60 ND ND Temporin-lLb 48 >150 >150 Temporin-lLc 125 >150 >150 29 WO 00/09553 PCTIUS99/18575 Rana berlandieri Brevinin-1Ba 2 ND ND Brevinin-lBb 1 3 10 Brevinin-1Be 13 ND ND Brevinin-lBd 3 7 7 Brevinin-1Be 3 15 ND Brevinin-lBf 8 19 ND Esculetin-2B 1 1 29 Ranatuerin-2B 1 1 35 Rana pipiens Brevinin-Ipa 7 14 5 Brevinin-lPb 5 14 7 Brevinin-1Pc 7 5 7 Brevinin-lPd 27 78 29 Esculetin-2P ND 10 ND Ranatuerin-2P 50 13 67 Temporin-IP 110 ND ND Rana clamitans Ranatuerin-1C 55 1.5 58 Ranalexin-1C 17 4 14 Ranatuerin-2Cb 40 2 46 Temporin-1Ca 100 NA NA Temporin-lCb 160 NA NA Temporin-ICc 100 NA NA 30 WO 00/09553 PCT/US99/18575 Rana grvlio Ranatuerin-IG 60 3.5 110 Ranatuerin-2G 150 19 >150 Ranalexin-IG 18 9 70 Temporin-1Ga 125 NA NA Temporin-lGb 55 NA NA Structure-Activity Study of ranatuerin-1. 5 Substitutions in the C-terminal domain of the molecule that increase the alpha-helical character are studied. Many increase potency towards gram negative bacteria. Ranatuerin-1 (SMLSVLKNLG' 0

KVGLGLVACK

2 0 INKQC) (SEQ ID NO: 8), isolated from the skin of the American bullfrog Rana catesbeiana, shows 10 antimicrobial activity against the gram-negative bacterium, Escherichia coli, the gram-positive bacterium Staphylococcus aureus, and the yeast, Candida albicans. The peptide is predicted to comprise three structural domains: alpha helix (residues 1- 8), beta-sheet (residues 11- 16) and beta-turn (residues 20-25). Substitution of Cys19 and Cys25 by Ser residues had only a minor effect on 15 potency demonstrating that the disulfide bridge is not necessary for activity. but deletion of the cyclic heptapeptide region produced an inactive analog. Substitution of GlylO, Glyl3 and Gly15 by either Lys or Glu residues produced analogs with increased a-helical content but with decreased or absent antimicrobial activity peptide thus demonstrating the importance of the central 20 beta-sheet region of the peptide. Substitution of Asn22 in the beta-turn region by Ala resulted in an increase in predicted alpha-helical character and an 8-fold increase in potency against E. coli. 31 WO 00/09553 PCT/US99/18575 In contrast, substitution of Ser4 in the N-terminal a-helical region by either Ala or Gly resulted in relatively minor effects on potency but deletion of residues (1-8) produced an inactive analog. Substitution of Lys7 and Lys 11 by Arg produced analogs with increased 5 positive charge but with decreased potency. The data demonstrate that the full sequence of the peptide is necessary for biological activity and that an increase in the alpha-helical content of the C-terminal region results in an increase in activity towards a gram-negative bacterium. 10 Ranatuerin Analog Synthesis All peptides were synthesized by solid-phase methodology on a 0.025 mmol scale on an Applied Biosystems model 432A peptide synthesizer using a 4-(2,4-dimethoxy-phenyl-Fmoc-aminomethyl)phenoxyacetamido-ethy resin (Perkin Elmer, Foster City, CA). Fmoc amino acid derivatives were activated 15 with O-benzotriazol-1-yl-N,N,N,N-tetramethyluronium hexafluorophosphate (1 equivalent), 1-hydroxybenzotriazole hydrate equivalentn) and diisopropylethylamine (2 equivalents) . Deprotection of the N-terminus by piperidine was monitored by on-line measurement of the conductance of the carbamate salt of the Fmoc group and optimum coupling times were determined 20 by the instrument in response to the deprotection times. The peptide was cleaved from the resin with trifluoroacetic acid/water/thioanisole/1,2-ethanedithiol (90.0/5.0/2.5/2.5) at 250 for 3 hr. The crude synthetic peptides were purified to near homogeneity by chromatography on a 1 x 25-cm Vydac 218TP510 C-18 reversed-phase HPLC 25 column (Separations Group, Hesperia, CA) equilibrated with 20 acetonitrile/water/ trifluoroacetic acid at a flow rate of 2 ml/min. The concentration of acetonitrile in the eluting solvent was raised to 49% over 60 min using linear gradients. Absorbance was measured at 214 and 280 mn and the major peak in the chromatogram was collected by hand. 32 WO 00/09553 PCT/US99/18575 The synthetic peptides were characterized by automated Edman degradation using an Applied Biosystems model 471A sequenator modified for on-line detection of phenylthiohydantoin amino acids under gradient elution conditions and by electrospray mass spectrometry using a Perkin Elmer Sciex 5 API 150EX single quadrupole instrument. The accuracy of mass determinations was BI 0.02%. Antimicrobial assays Minimal inhibitory concentrations (MICs) of the peptides were 10 determined by a standard microdilution method using 96-well microtiter cell culture plates as previously described. Serial dilutions of the peptides in Mueller Hinton broth (50 mL) were incubated with an inoculum (50 mL of 103 CFU/mL) from an overnight culture of Escherichia coli (ATCC 25922) and Staphylococcus aureus (NCTC 8325), for 18 h at 37 OC in a humidified atmosphere of 5% C02 15 in air. Incubations with Candida albicans (ATCC 90028) were carried out in RPMI 1640 medium for 48 h at 35 OC. After incubation, the absorbance at 550 nm of each well was determined using a M.A. Bioproducts model MA308 microtiter plate reader. The MIC of each peptide was taken as the lowest concentration where no visible growth was observed. In order to monitor the 20 validity of the assay, incubations with E. coli and S. aureus were carried out in parallel with increasing concentrations of the broad-spectrum antibiotic, bacitracin and incubations with C. albicans in parallel with amphotercin B. The MIC's are presented in 25 Table 3. TABLE 3 MIC values (pm) Analog E. coli S. aureus C. albicans 33 WO 00/09553 PCT/US99/18575 Analog E. coli S. aureus C. albicans Ranatuerin- 1 3 50 70 [Serl9,Ser25]Ranatuerin-1 14 28 110 [Ala4, Serl9,Ser25]Ranatuerin-1 10 190 110 [Gly4, Serl9,Ser25]Ranatuerin-1 28 NA 140 [Arg7, Serl9,Ser25]Ranatuerin 1 14 190 190 [Arg11, Serl9,Ser25]Ranatuerin 1 28 110 110 [Lys13,Serl9,Ser25]Ranatuerein-1 190 NA NA [Ala22, Serl9,Ser25]Ranatuerin-1 1.5 200 110 [LyslO,Lysl3Lysl5- 120 NA NA Serl9,Ser25]Ranatuerin-1 [GlulO,Glul3,Glul5- NA NA NA Ser19,Ser25]Ranatuerin-1 Ranatuerin-1(1-19)fragment NA NA NA Ranatuerin-1(9-25)fragment NA NA NA NA: no activity up to 200 mM 34

Claims (11)

1. An antibacterial peptide selected from any of the following Rana peptide families wherein each peptide of a family is in the form of a C-terminus carboxylic acid, a C-terminus amide or a C-terminus ester, wherein the single or multiple dashed lines of the Ranatuerin-2 family peptides signify a single bond between the two amino acid residues adjacent the dashed lines, and wherein each dashed line of the Ranatuerin-2 family peptides stands for an amino acid residue position for the purpose of aligning the amino acid residues of the peptides of that family so that the residues are homologously positioned: Ranatuerin-1 family Ranatuerin-1 SMLSVLKNLGKVGLGFVACKINKQC (SEQ ID NO: 8) Ranatuerin-IG SMISVLKNLGKVGLGFVACKVNKQC (SEQ ID NO: 9) Ranatuerin-IC SMLSVLKNLGKVGLGLVACKINKQC (SEQ ID NO: 10) Ranatuerin-2 family Ranatuerin-2 GLFLDTLKGAAKD-----AGK-LEGLKCKITGCKLP (SEQ ID NO: 12) Ranatuerin-3 GFL-DIIKNLGKTF----AGHMLDKIKCTIGTCPPSP (SEQ ID NO: 13) Ranatuerin-2P GLM DTVKNVAKNL----AGHMLDKLKCKITGC (SEQ ID NO: 14) Ranatuerin-2B GLL DTIKGVAKTV----AASMLDKLKCKISGC (SEQ ID NO: 15) Ranatuerin-2Ca GLFLDTLKGAAKDV----AGKLLEGLKCKIAGCKP (SEQ ID NO: 16) Ranatuerin-2Cb GLFLDTLKGL--------AGKLLQGLKCIKAGCKP (SEQ ID NO: 17) Ranatuerin-2La GI-LDSFKGVAKGVAKDLAGKLLDKLKCKITGC (SEQ ID NO: 18) Ranatuerin-2Lb GILSSI-KGVAKGVAKNVAAQLLDTLKCKITGC (SEQ ID NO: 19) Ranatuerin-2G GLLLDTLKGAAKDI----AGIALEKLKCKITGCKP (SEQ ID NO: 20) Esculentin-2 family Esculentin-2L GILSLFTGGIKALGKTLFKMAGKAGAEHLACKATNQC (SEQ ID NO: 22) 35 WO 00/09553 PCT/US99/18575 Esculentin-2B GLFSILRGAAKFASKGLGKDLTKLGVDLVACKISKQC (SEQ ID NO: 23) Esculentin-2P GFSSIFRGVAKFASKGLGKDLARLGVNLVACKISKQC (SEQ ID NO: 24) Brevinin-i family Ranatuerin-4 FLPFIARLAAKVFPSIICSVTKKC (SEQ ID NO: 26) Brevinin-ILa FLPMLAGLAASMVPKLVCLITKKC (SEQ ID NO: 27) Brevinin-lLb FLPMLAGLAASMVPKFVCLITKKC (SEQ ID NO: 28) Brevinin-1Ba FLPAIAGMAAKFLPKIFCAISKKC (SEQ ID NO: 29) Brevinin-1Bb FLPAIAGMAAKFLPKIFCAISKKC (SEQ ID NO: 30) Brevinin-iBc FLPFIAGVAAKFLPKIFCAISKKC (SEQ ID NO: 31) Brevinin-1Bd FLPAIAGVAAKFLPKIFCAISKKC (SEQ ID NO: 32) Brevinin-1Be FLPAIVGAAAKFLPKIFCVISKKC (SEQ ID NO: 33) Brevinin-lBf FLPFIAGMAANFLPKIFCAISKKC (SEQ ID NO: 34) Brevinin-IPa FLPIIAGVAAKVFPKIFCAISKKC (SEQ ID NO: 35) Brevinin-IPb FLPIIAGIAAKVFPKIFCAISKKC (SEQ ID NO: 36) Brevinin-lPc FLPIIASVAAKVFSKIFCAISKKC (SEQ ID NO: 37) Brevinin-lPd FLPIIASVAANVFSKIFCAISKKC (SEQ ID NO: 38) Brevinin-iPe FLPIIASVAAKVFPKIFCAISKKC (SEQ ID NO: 39) Ranalexin-1 family Ranalexin-IC FLGGLMKAFPALICAVTKKC (SEQ ID NO: 41) Ranalexin-IG FLGGLMKIIPAAFCAVTKKC (SEQ ID NO: 42) Temporin-A family wherein the C-terminus is a simple carboxamide Ranatuerin 5 FLPIASLLGKYL (SEQ ID NO: 44) Ranatuerin 6 FISAIASMLGKFL (SEQ ID NO: 45) Ranatuerin 7 FLSAIASMILGKFL (SEQ ID NO: 46) Ranatuerin 8 FISAIASFLGKFL (SEQ ID NO: 47) Ranatuerin 9 FLFPLITSFLSKVL (SEQ ID NO: 48) Temporin-ICa FLPFLATLLSKVL (SEQ ID NO: 49) Temporin-lCb FLPFLAKILTGVL (SEQ ID NO: 50) Temporin-1Cc FLPLPASLFGKKL (SEQ ID NO: 51) Temporin-lPa FLPIVGKLLSGLL (SEQ ID NO: 52) 36 WO 00/09553 PCT/US99/18575 Temporin-ILc FLPILINLIIHKGLL (SEQ ID NO: 53) Temporin-B Family wherein the C-terminus is a simple carboxamide Temporin-ILa VLPLISMALGKLL (SEQ ID NO: 55) Temporin-lLb NFLGTLINLAKKIM (SEQ ID NO: 56) Temporin-lGa SILPTIVSFLSKFV (SEQ ID NO: 57) Temporin-lGb SILPTIVSFLSKFL (SEQ ID NO: 58) Temporin-lGc SILPTIVSFLTKFIL (SEQ ID NO: 59) Temporin-lGd FUPLIASFLSKFIL (SEQ ID NO: 60)

2. A modified Rana peptide of any of the following formulas wherein each formula corresponds to a single Rana peptide family of claim 1 and wherein the symbols X, B, Z, U, 0, J' and J and their position/location within a formula designate either any of the amino acid residues occurring at the same position within the other peptides of the same family or a conservative substitution of an amino acid residue for the amino acid substitution of an amino acid residue at the same position for any of the peptides within the same family: (i) a Ranatuerin-1 family modified Rana peptide of the formula SMXSVLKNLGKVGLGXVACKXNKQC (SEQ ID NO: 11) having the designation Ranatuerin-1 mod; (ii) a Ranatuerin-2 family modified Rana peptide of the formula GBBBBBBKBBBBBBBBBBABBBBBBBKCBBBBCBBB (SEQ ID NO: 21) and having the designation Ranatuerin-2 mod; 37 WO 00/09553 PCT/US99/18575 (iii) an Esculentin-2 family modified Rana peptide of the formula GZZSZZZGZZKZZZKZLZKZZZZZGZZZZACKZZZQC (SEQ ID NO: 22) and having the designation Esculentin-2 mod; (iv) a Brevinin-1 family modified Rana peptide of the formula FLPUUUUUAAUUUUUUUCUUUKKC (SEQ ID NO: 40) and having the designation Brevinin-lmod; (v) a Ranalexin-1 family modified Rana peptide of the formula FLGGLMKJ'J'PAJ'J'CAVTKKC (SEQ ID NO: 43) and having the designation Ranalexin mod; (vi) a Temporin-A family modified Rana peptide of the formula FOOOOOOOOOOOLO (SEQ ID NO: 54) and having the designation Temporin-A mod; (vii) a Temporin-B family modified Rana peptide of the formula JJJJJIJSFLJKFJL (SEQ ID NO: 61) and having the designation Temporin-B mod.

3. A modified Rana peptide having the amino acid sequence of any of the Rana peptides of claim I wherein one or more of the following amino acid substitutions have been made: a) alanine for cysteine; b) serine for cysteine; c) alanine for glycine; d) valine for glycine; e) lysine for glycine; f) glutamine for glycine; g) arginine for lysine; h) alanine for asparagine i) coupling a CIO to C 20 fatty acid to the lysine side chain.

4. A truncated Rana peptide of claim 1. 38 WO 00/09553 PCT/US99/18575

5. A composition comprising a purified, antibacterial extract of the skin of a mature Ranid frog of the species selected from catesbeiana, luteiventris, berlandieri, grylio, clamitans and pipiens.

6. A pharmaceutical composition comprising an effective antibacterial amount of a Rana peptide of claim 1 and a suitable pharmaceutical carrier.

7. A pharmaceutical composition comprising an effective antibacterial amount of a modified Rana peptide of claim 2 and a suitable pharmaceutical carrier.

8. A pharmaceutical composition comprising an effective antibacterial amount of a truncated Rana peptide of claim 3 and a suitable pharmaceutical carrier.

9. A method of treatment of a bacterial infection in a patient comprising administering to the patient an antibacterially effective amount of a Rana peptide of claim 1, a modified Rana peptide of claim 2 or 3, or a truncated Rana peptide of claim 4, or a composition of claim 5, or a pharmaceutical composition of claim 6, 7 or 8.

10. A Rana peptide of claim 1 or 2 wherein the peptide is the amide or ester, the amide being a simple amide or an amide of a Cl to C10 aliphatic or aromatic primary, secondary or tertiary amine, and the ester being an ester of a C1 to C10 aliphatic or aromatic alcohol.

11. A Rana peptide of claim 1 selected from the Temporin A or Temporin B family wherein the C-terminus is a carboxylic acid. 39